A61K 40/4202
Receptors, cell surface antigens or cell surface determinants
Official title: {Receptors, cell surface antigens or cell surface determinants}
A61K40/4202 (Receptors, cell surface antigens or cell surface determinants) appears on 2,108 US grants and 5,781 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,108
- Published applications
- 5,781
- Assignees
- 1,452
- Inventors
- 8,179
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 5 | 20 |
| 2003 | 4 | 16 |
| 2004 | 2 | 25 |
| 2005 | 3 | 20 |
| 2006 | 4 | 21 |
| 2007 | 4 | 14 |
| 2008 | 7 | 23 |
| 2009 | 7 | 21 |
| 2010 | 16 | 27 |
| 2011 | 11 | 30 |
| 2012 | 15 | 29 |
| 2013 | 15 | 38 |
| 2014 | 19 | 41 |
| 2015 | 29 | 57 |
| 2016 | 35 | 90 |
| 2017 | 45 | 157 |
| 2018 | 58 | 258 |
| 2019 | 86 | 329 |
| 2020 | 170 | 490 |
| 2021 | 189 | 585 |
| 2022 | 234 | 712 |
| 2023 | 233 | 666 |
| 2024 | 287 | 830 |
| 2025 | 354 | 719 |
| 2026 | 261 | 562 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 40/421Immunoglobulin superfamily1,204
- A61K 40/4214Receptors for cytokines506
- A61K 40/4203Receptors for growth factors413
- A61K 40/4224Molecules with a "cd" designation not provided for elsewhere217
- A61K 40/4221Cd20157
- A61K 40/422Ephrin receptors [eph]31
- A61K 40/4222Cd38 not igg26
- A61K 40/4223Cd44 not igg8
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies343US 6,410,319 B1City of Hope · 2002